<< Failures in Canadian health policy | First Analyses of TYRX's AIGISRx Anti-Bacterial Envelope Retrospective Registry >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski

New market research on Bristol-Myers Squibb released

Published on September 21, 2009 at 7:24 AM · No Comments

Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Bristol-Myers Squibb Co.: PharmaVitae Profile

http://www.reportlinker.com/p0148175/Reportlinker-Adds-Bristol-Myers-Squibb-Co-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector
Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
Investigate the strength of BMS's pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.

http://www.reportlinker.com

3eecd1a7-e9f1-4720-917d-d5be8794ec2d|0|.0

Posted in:

Tags: Abilify, Antipsychotic, Apixaban, Hepatitis B, Immunology, Nervous System, Oncology, Onglyza, Pfizer, Plavix, Sprycel, Truvada, Zyprexa

Related posts

FDA accepts Gilead's Truvada sNDA and grants Priority Review to reduce risk of HIV-1 infectionGilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted ...
Merck announces FDA approval for GARDASIL against HPV-related anal cancerMerck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Dru...
Venous thromboembolism drugs to experience robust growth by 2019Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and he...
Mutation in ion channel that changes its dynamics is implicated in epilepsy: ScientistsIn 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the ...
MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapyDasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia,...
Viagra promotes fetal growth in pregnant sheep, raises hope for preventing fetal development problems in humansA joke among two Texas AgriLife Research scientists later turned into a fully-funded study found Via...
Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2...
Oncotype DX multigene expression test for breast cancer patientsIn an effort to provide breast cancer patients with prompt, critical information about treatment opt...
Report says 650,000 cancer deaths avoided between 1990 and 2005The American Cancer Society's annual cancer statistics report finds that 15 years of steady declines...
Lilly receives complete response letter for Olanzapine LAI for treatment of schizophreniaEli Lilly and Company has announced that it received a complete response letter from the U.S. Food a...
Thailand wins round two in battle to access cheaper AIDS drugsThe military government in Thailand has won the second round in it's battle to access cheaper AIDS d...
FDA approves Exelon to treat dementia of Parkinson's diseaseFDA approves Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associate...
FDA issues public health advisory for antipsychotic drugsThe Food and Drug Administration (FDA) has issued a public health advisory to alert health care prov...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.